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Abstract
Background: A living‐donor (adult) kidney transplantation in young children requires 
an increased cardiac output to maintain adequate perfusion of the relatively large 
kidney. To achieve this, protocols commonly advise liberal fluid administration guided 
by high target central venous pressure. Such therapy may lead to good renal out‐
comes, but the risk of tissue edema is substantial.
Aims: We aimed to evaluate the safety and feasibility of the transpulmonary ther‐
modilution technique to measure cardiac output in pediatric recipients. The second 
aim was to evaluate whether a cardiac output‐guided hemodynamic therapy algo‐
rithm could induce less liberal fluid administration, while preserving good renal re‐
sults and achieving increased target cardiac output and blood pressure.
Methods: In twelve consecutive recipients, cardiac output was measured with 
transpulmonary thermodilution (PiCCO device, Pulsion). The algorithm steered ad‐
ministration of fluids, norepinephrine and dobutamine. Hemodynamic values were 
obtained before, during and after transplantation. Results are given as mean (SD) 
[minimum‐maximum].
Results: Age and weight of recipients was 3.2 (0.97) [1.6‐4.9] yr and 14.1 (2.4) 
[10.4‐18] kg, respectively. No complications related to cardiac output monitoring oc‐
curred. After transplantation, cardiac index increased with 31% (95% CI = 15%‐48%). 
Extravascular lung water and central venous pressure did not change. Fluids given de‐
creased from 158 [124‐191] mL kg−1 in the first 2 patients to 80 (18) [44‐106] mL kg−1 in 
the last 10 patients. The latter amount was 23 mL kg−1 less (95% CI = 6‐40 mL kg−1) than 
in one recent study, but similar to that in another. After reperfusion, all patients received 
norepinephrine (maximum dose 0.45 (0.3) [0.1‐0.9] mcg kg−1 min−1). Patient and graft 
survivals were 100% with excellent kidney function at 6 months post‐transplantation.
Conclusion: Transpulmonary thermodilution‐cardiac output monitoring appeared to 
be safe and feasible. Using the cardiac output‐guided algorithm led to excellent renal 
results with a trend toward less fluids in favor of norepinephrine.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
© 2019 The Authors. Pediatric Anesthesia published by John Wiley & Sons Ltd
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1  | INTRODUC TION
Renal transplantation is the therapy of choice for children with end‐
stage renal disease. Living‐donor kidney transplantation (LDKT) has 
benefits including less acute rejection, better catch‐up growth and 
higher quality of life.1 Living‐donor kidney transplantation in chil‐
dren implies an adult donor because children are not considered as 
living donors for ethical reasons. In small children, this leads to a 
large donor‐recipient size mismatch. The normal blood flow to one 
adult kidney is approximately 0.5 L min−1 or 10% of the cardiac 
output (CO), whereas the CO of a 1‐year‐old child is approximately 
2.5 L min−1.2 Therefore, kidney transplantation in a young child im‐
plies large hemodynamic changes to meet the “adult” flow and pres‐
sure requirements of the donor kidney. These changes are scarcely 
quantified in the literature. Increased aortic blood flow and CO have 
been reported, but the reported measuring techniques are ill‐suited 
for routine use during surgery.3,4
It is uncertain how to guarantee sufficient blood flow through 
the transplanted kidney, as evidence‐based guidelines do not 
exist. Hemodynamic therapy protocols commonly advise liberal 
fluid administration guided by high target central venous pres‐
sure (CVP) and arterial blood pressure (ABP).5,6 However, ABP 
and CVP are known to poorly reflect CO and organ blood flow or 
predict fluid responsiveness.7 Therefore, such therapy may lead 
to good renal outcomes, but the risk of fluid overload is substan‐
tial. This is illustrated by the high incidence of pulmonary edema, 
prolonged ventilator support, and renal replacement therapy in 
these patients.5,6
In 2012, our center started a special program for LDKT in 
children under the age of four. Designing the protocol for periop‐
erative hemodynamic support, we aimed at a physiology‐based 
approach. The high target CVP advocated in literature was aban‐
doned, aiming for less liberal fluid administration. This accords 
with many reports questioning the use of CVP as a reliable mon‐
itor of fluid status in adults.8 Based upon our experience with 
advanced hemodynamic monitoring in children, we chose the 
transpulmonary thermodilution (TPTD) technique to measure CO 
as this technique has been validated and is designated as the gold 
standard in children.9,10
As this is the first report on TPTD‐CO monitoring during LDKT 
with large donor‐recipient size mismatch, our first goal was to eval‐
uate the safety and feasibility of the technique and analyze the 
hemodynamic changes. The second goal was to evaluate whether 
this CO‐guided hemodynamic therapy algorithm induced a reduc‐
tion in intraoperative fluid administration compared with other re‐
ports, while achieving increased target CO and ABP with good renal 
outcome.
2  | MATERIAL S AND METHODS
2.1 | Study design
All children with a bodyweight below 20 kg who underwent a LDKT 
between the start of the program in October 2012 and September 
2016 were consecutively included in this prospective observational 
study. Two anesthesiologists dedicated to the program alternately 
provided the anesthetic care using a standardized anesthesia proto‐
col and a hemodynamic therapy algorithm (Figure 1).
2.2 | Intraoperative management
All patients underwent extensive pre‐operative screening, including 
cardiac evaluation. The donor nephrectomies were laparoscopic pro‐
cedures. Donor kidneys were inserted right‐sided intra‐abdominally 
through a transverse abdominal incision with vascular anastomoses 
on the aorta and inferior caval vein. All recipients were treated by 
the TWIST immunosuppressive protocol.11
Anesthesia was induced with sevoflurane by face mask or intra‐
venous thiopental (3‐5 mg kg−1). After administration of intravenous 
rocuronium (0.5‐1 mg kg−1) an endotracheal tube was placed and pos‐
itive pressure ventilation started with a tidal volume of 6‐8 mL kg−1 
and positive end‐expiratory pressure of 4‐6 cm H2O. Anesthesia was 
maintained with sevoflurane (end‐tidal concentration 2.0%‐2.2%) 
in oxygen/air and intravenous sufentanil. Target end‐expiratory 
partial pressure for CO2 was 33‐38 mm Hg. Cefuroxim was given 
K E Y W O R D S
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pediatric, renal transplantation
What is already known
• Cardiac output increases after adult donor kidney trans‐
plantation in small children.
• Perioperative hemodynamic therapy is currently 
based on high target central venous pressures leading 
to liberal fluid administration with the risk of tissue 
edema.
What this article adds
• The transpulmonary thermodilution technique for moni‐
toring cardiac output is feasible and safe in living donor 
kidney transplantation in children under 20 kg.
• Cardiac output‐guided hemodynamic therapy seems 
to lead to less liberal intra‐operative administration of 
fluids in favor of norepinephrine while achieving good 
renal outcomes.
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before surgical incision as a prophylactic antibiotic. Mannitol 10% 
(0.5 L 1.73 m−2) was administered 10 minutes before reperfusion of 
the donor kidney. No diuretics were given.
2.3 | Hemodynamic instrumentation
A 22 G and a 4 Fr catheter were placed in a radial artery and the 
right internal jugular vein, respectively. When the dialysis catheter 
was already in place, this was used as the central venous catheter. 
Heart rate (HR), ABP, and CVP were continuously monitored (Philips 
data monitor). A thermistor‐tipped PiCCO‐catheter (3 Fr, 7 cm) was 
inserted (ultrasound‐guided) in the left femoral artery to measure 
TPTD‐CO. This site was chosen as it was as far away as possible from 
the vascular anastomosis with all transplantations right sided. The 
catheter was connected to the PiCCO2 device. The device was con‐
nected to a laptop computer with PiCCOwin‐software for storage of 
hemodynamic measurements and curves (Pulsion). The curves were 
reviewed for quality assessments to assure that they were techni‐
cally correct.
2.4 | Data collected
Patients' demographic data, pretransplantation (co‐)morbidities, es‐
timated glomerular filtration rate (eGFR), presence of dialysis, and 
recipient‐donor weight ratio were recorded. Also, duration of anes‐
thesia, blood loss, vasoactive drug and fluid administration, time to 
first diuresis, time to creatinine nadir, time to PiCCO‐catheter re‐
moval, duration of hospital stay, complications, and eGFR 6 months 
after transplantation were recorded.
TPTD‐CO measurements were performed at time points left 
to the discretion of the attending physician. However, three mea‐
surements were done at fixed moments in time and were used 
in our study. All measurements were done in a hemodynamically 
stable period. Stable conditions were defined as variance in hemo‐
dynamic variables of <10% and no change in fluids or vasopressor 
administration in the last 15 minutes. The first measurement was 
performed after induction of anesthesia, before surgical incision 
(t0), the second during surgery after reperfusion of the donor kid‐
ney (t1), and the third in the ICU just before removal of the PiCCO 
F I G U R E  1   Algorithm of perioperative 
hemodynamic therapy in pediatric kidney 
transplantation guided by blood pressure 
and cardiac output measurements. 
NaHCO3, sodium bicarbonate; MAP, Mean 
Arterial Pressure; CO, cardiac output; 
CI, Cardiac Index. Fluid responsiveness 
is defined as an increase in CO (or 
stroke volume) of >10%. *Consider using 
balanced solution (like lactated Ringers' 
solution) to prevent hyperchloremic 
acidosis
     |  953VOET ET al
catheter (t2). The PiCCO catheter was removed when vasoactive 
medication was no longer necessary to optimize hemodynamics. 
At t0, t1, and t2 hemodynamic variables were recorded. CO was 
measured as the mean of three consecutive measurements with 
central venous injections of 10 mL iced saline 0.9%. To prevent cal‐
culation bias by the PiCCO software, only the TPTD measurements 
with absolute values of CO and extravascular lung water were 
used. Cardiac output was divided by the mean HR obtained during 
TPTD measurements to calculate stroke volume. Cardiac output 
and stroke volume were adjusted for body surface area, thus yield‐
ing CI, expressed as L min−1 m−2 and stroke volume index (SVI), ex‐
pressed as mL m−2. Extravascular lung water was adjusted for body 
weight, yielding extravascular lung water index (EVLWI) expressed 
as mL kg−1. Global end diastolic volume was not used and not stud‐
ied because of lack of validation in children. EVLWI was not used to 
guide therapy but was studied with regard to individual changes as 
a marker of pulmonary edema.
2.5 | Hemodynamic therapy algorithm
Basic fluid requirements were calculated according to the 4‐2‐1‐
rule of Holliday and Segar. Intravenous fluids, inotropic and vaso‐
pressor support were titrated according to the algorithm shown 
in Figure 1 to reach target CO and mean arterial pressure (MAP). 
Crystalloids were chosen as primary fluids as semisynthetic col‐
loids have been associated with adverse outcomes in adult renal 
transplantation.12 Per protocol, albumin was considered as an al‐
ternative colloid.
Reference values for normal cardiac index (CI) in children show 
a wide range.13 Patient's CI at t0 was therefore used as normal ref‐
erence or baseline value. We aimed at a higher CI at t1 compared 
with baseline and of at least 3.5 L min−1 m−2. This value was a prag‐
matic choice aiming at a higher than “normal” CI for optimal perfu‐
sion of the donor kidney. The target MAP >65 mm Hg was chosen 
as acceptable lower margin during anesthesia as all donors had nor‐
mal ABP. Both targets were evaluated for their appropriateness by 
visually judging the perfusion of the donor kidney at the moment of 
reperfusion. If needed, target CI and MAP were adjusted to higher 
values. Only TPTD‐CO measurements were used to guide therapy. 
Although the PiCCO technology allows to continuously measure 
CO, using pulse contour analysis, this was not used because it is 
considered unreliable when frequent changes in hemodynamic 
support occur.
2.6 | Statistical analysis
Results for all variables are given as mean (SD) [minimum‐maximum], 
unless stated otherwise.
A one‐way analysis of variance (ANOVA) for repeated measure‐
ments was used to evaluate the null hypothesis that there is no 
difference among patients' mean values for hemodynamic physio‐
logical variables obtained at the three measuring points t0, t1 and 
t2. ANOVA used Greenhouse‐Geisser correction for non‐sphericity 
if needed. If the ANOVA revealed a difference between the values, 
post hoc analysis using Bonferroni multiple comparisons test was 
done. Student's t‐test for paired data was used to compare CVP 
measurements.
A two‐sample t‐test for groups with unequal variances (Welch's 
test) was used to compare intraoperative fluids given to our last 10 
patients with those reported in two recent papers on intraoperative 
management in pediatric kidney transplantation.5,6
Data were analyzed using GraphPad Prism V7.0d (GraphPad 
Software) and IBM SPSS Statistics V21.0. P < .05 was considered 
statistically significant.
3  | RESULTS
Twelve patients entered the study. Table 1 shows key figures of their 
perioperative characteristics.
3.1 | Patients' characteristics
Table 2 shows characteristics of individual patients, their eGFR 
before and after LDKT, and postoperative days to extubation. 
Preoperative echocardiography showed structural normal hearts 
with good systolic function in all patients. In 1 patient a pulmo‐
nary artery stenosis and a bidirectional shunt through the fora‐
men ovale had been corrected at infancy. All donors were healthy 
family related adults (seven females) with a mean age of 36.2 (7.3) 
[24‐45] yr.
TA B L E  1   Patients' perioperative characteristics
 N = 12
Gender (number of boys/girls) 8/4
Age (y) 3.2 (0.97) [1.6‐4.9]a
Weight (kg) 14.1 (2.4) [10.4‐18]
Body surface area (m2) 0.59 (0.07) 
[0.46‐0.69]
eGFR before transplantation (mL min−1 
1.73 m−2)
7.6 (3.5) [3.6‐15.7]
Recipient‐donor weight ratio 0.18 (0.05) 
[0.11‐0.28]
Duration of anesthesia (min) 294 (37) [215‐340]
Blood loss (mL kg−1) 8.3 (4.8) [0‐15]
Time to creatinine nadir (d after 
transplantation)
<2
Time to PiCCO‐catheter removal (d) 4.2 (2.8) [1‐12]
Hospital stay (d) 25.2 [15‐44]
Graft survival, 6 mo after transplantation (%) 100
eGFR, 6 mo after transplantation (mL min−1 
1.73m−2)
100.5 (27.8) 
[65‐155]
Abbreviation: eGFR, estimated glomerular filtration rate.
aResults are given as mean (standard deviation) [minimum‐maximum], 
unless stated otherwise 
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3.2 | Intraoperative hemodynamic therapy
At t0, four patients received norepinephrine 0.07 (0.04) 
[0.01‐0.1] mcg kg−1 min−1 and one received dobutamine 
(3.8 mcg kg−1 min−1). Following reperfusion of the donor kidney all re‐
cipients experienced a decrease in ABP of >20%. Patients' target MAP 
and CI were quickly restored using fluid loading and increasing vaso‐
pressor therapy. After reperfusion, all patients received norepinephrine 
(maximum dose 0.45 (0.3) [0.1‐0.9] mcg kg−1 min−1) and eight received 
dobutamine (maximum dose 3.4 (1.7) [1.9‐6.3] mcg kg−1 min−1).
Figure 2A shows the fluids administered intraoperatively. Patients 
received a total of 93 (37) [44‐191] mL kg−1 that included crystalloids, 
mannitol and the iced normal saline used for the CO measurements. 
Per protocol, of this total, 20 mL kg−1 were given prior to reperfusion. 
Fluid administration was 158 [124‐191] mL kg−1 in the first two pa‐
tients. It decreased to 80 (18) [44‐106] mL kg−1 in the last 10 patients, 
which is 23 (8) mL kg−1 less than the 103 (61) mL kg−1 of crystalloids 
found by Michelet and co‐authors5 (95% CI = 6‐40 mL kg−1; P = .01). 
They also reported 16 (14) mL kg−1 albumin being given apart from the 
crystalloids. Our patients did not receive albumin.
TA B L E  2   Characteristics of individual patients
Patient
Age on KT Weight BSA Gender
Dialysis or 
Pre‐emptive Kidney disease
eGFR
Time to 
extubation
before KT 6 mo 
after KT
(y) (kg) (m2) (m/f)
(mL min−1 
1.73 m−2) (d after KT)
1 4.2 14.6 0.62 f P dysplastic kidneys 6.4 70 1
2 2.9 13 0.54 m D urethral valves 7.2 74 4
3 2.9 18 0.69 m P urethral valves 3.6 95 3
4 3.5 14.6 0.62 m P urethral valves 6 79 2
5 3.2 14.2 0.6 m P dysplastic kidneys 4.7 65 3
6 2.4 13.2 0.58 m P urethral valves 8 103 4
7 2 10.4 0.47 m P dysplastic kidneys 6.7 130 5
8 1.6 10.6 0.46 f D ciliopathy 10.8 130 0
9 3.3 15.5 0.65 m P nephrotic syndrome 15.7 86 0
10 3 12 0.55 f D nephrotic syndrome 4.2 155 0
11 4.4 15.7 0.63 m P dysplastic kidneys 6 105 0
12 4.9 17.2 0.69 f P ciliopathy 12 114 0
Abbreviations: BSA, body surface area (Mosteller formula); D, patient on dialysis before transplant; eGFR, estimated glomerular filtration ratio; KT, 
kidney transplantation; m/f, male/female; mo, months; P, pre‐emptive transplantation.
F I G U R E  2   Intravenous fluids 
administered to the consecutive patients 
during surgery (n = 12). Patients are 
numbered consecutively as in Table 2. 
2A: Total fluids expressed as mL·kg−1. 
Fluids are crystalloid (including sodium 
bicarbonate) and mannitol solutions 
plus the iced saline 0.9% used for the 
measurement of cardiac output with 
transpulmonary thermodilution. 2B: Total 
fluids expressed as mL·kg−1·h−1. Each black 
circle represents one patient. The thick 
solid line is a 2‐patient moving average.
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Figure 2B shows the amount of fluids per kg body weight given hourly. 
Patients received 18.9 (6.4) [8.9‐33.7] mL kg−1 h−1. The first two received 
29.8 [25.8‐33.7] mL kg−1 h−1, the last ten 16.7 (3.8) [8.9‐21.9] mL kg−1 h−1. 
The difference with the amount found by Taylor and co‐authors6 was 
not significant (95% CI = −3.0‐3.5 mL kg−1 h−1; P = .87).
Eight patients received blood products: 14 (8) [6‐28] mL kg−1. 
Considering crystalloids and blood products together, patients re‐
ceived 102 (38) [62‐207] mL kg−1.
3.3 | Hemodynamic values
All hemodynamic data could be collected on the three measuring 
points, except for CVP. CVP was measured in 10 patients at t0 
and t1.
Table 3 shows average absolute values for all hemodynamic 
variables, differences among the three measuring points and 
P‐values. Results of repeated measures ANOVA indicated a statis‐
tically significant time effect for HR, SVI, CI and MAP. Follow‐up 
comparisons indicated that HR, SVI, CI, and MAP increased be‐
tween t0 and t1. There was a further increase in MAP between t1 
and t2, but not for HR, SVI and CI. MAP increased with 66% (95% 
CI = 34%‐98%) between t0 and t2. At t2 none of the patients re‐
ceived norepinephrine or dobutamine. CVP values did not change 
between t0 and t1. Also, no statistically significant time effect for 
EVLWI was found.
Figure 3 shows the percentage changes between the three mea‐
suring points for the physiologically coupled variables HR, SVI, and CI. 
Between pretransplantation (t0) and post‐transplantation measuring 
points (t2) CI increased with a mean of 31% (95%CI = 15%‐48%) and 
HR with 22% (95%CI = 9%‐34%). SVI increased between t0 and t1 
with 18% (95%CI = 10%‐26%), but did not show a statistically signif‐
icant change between t0 and t2.
TA B L E  3   Values of hemodynamic variables obtained at three different time points: pre‐transplantation (t0), post‐reperfusion (t1) and in 
the intensive care unit, without hemodynamic support (t2) (n = 12)
 
Absolute values Differences between absolute values
(mean (SD) [minimum‐maximum]) (mean (95% confidence interval))
t0 t1 t2 t1‐t0 t2‐t1 t2‐t0
HR (bpm) 99 (18) [67‐125] 116 (13) [96‐135] 119 (23) [83‐162]a 17 (2‐32)b1 3 (−17‐23)2 20 (5‐35)b3
SVI (mL m−2) 45 (7) [32‐59] 53 (7) [38‐65] 49 (10) [29‐64]a 8 (3‐12)b4 −4 (−9‐1)5 4 (−3‐11)6
CI (L min−1 m−2) 4.4 (1.0) [2.1‐6.2] 6.0 (0.8) [4.6‐7.7] 5.7 (1.3) [2.4‐7.4]a 1.6 (1.0‐2.3)b7 −0.3 (−1.2‐0.6)8 1.3 (0.5‐2.1)b9
MAP (mm Hg) 59 (13) [46‐83] 73 (7) [62‐83] 94 (19) [62‐116]a 14 (6‐22)b10 21 (6‐36)b11 35 (16‐53)b12
CVP (mm Hg) 9.5 (3) [5‐14] 9.8 (4) [4‐17] c 0.3 (−1.9‐2.5) c c
EVLWI (mL·kg−1) 13 (6) [8‐29] 12 (3) [8‐17] 11 (4) [6‐17] NA NA NA
Note: NA means not applicable because the ANOVA for repeated measurements yielded P = .31 (EVLWI).
Abbreviations: CI, cardiac index; CVP, central venous pressure; EVLWI, extravascular lung water index; HR, heart rate; L, liter; MAP, mean arterial 
pressure; SVI, stroke volume index.
aStatistically significant effect of time (repeated measures ANOVA); P‐values are: .01 (HR), .007 (SVI), <.0001 (CI) and <.0001 (MAP). 
bStatistically significant difference (95% confidence interval includes zero) between time points; Bonferroni adjusted P‐values are as follows: .022(1), 
>.999(2), .008(3), .002(4), .154(5), .472(6), <.0001(7), >.999(8), .003(9), .001(10), .007(11) and .0007(12). 
cCVP was obtained in 10 patients at 2 times points; the difference between values for CVP was not statistically significant (Student's t‐test for paired 
data: P = .76). 
F I G U R E  3   Percentage changes 
between three measuring points for three 
physiologically coupled variables: HR, 
heart rate; SVI, stroke volume index and 
CI, cardiac index. An error bar represents 
one standard deviation (n = 12). The 
three y‐axes have the same length of 75%. 
t0: after induction of anesthesia, before 
surgical incision; t1: after reperfusion 
of the donor kidney during a stable 
hemodynamic situation; t2: after cessation 
of hemodynamic support, at the intensive 
care unit
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3.4 | Postoperative data
All donor kidneys displayed diuresis shortly after reperfusion. Early 
complications were drug‐induced delirium in two patients, septicemia 
in one and early postoperative hemorrhage in another, necessitating 
reoperation. In a patient with nephronophthisis (ciliopathy with medul‐
lary renal cysts) and pre‐existent liver fibrosis, excessive postoperative 
ascites and lymph leakage were present. Perfusion problems of the leg 
distal from the PiCCO catheter or complications at the site of anasto‐
mosis were not encountered. After ICU admission, vasopressor therapy 
could be tapered down in all patients. The PiCCO catheter was re‐
moved in ICU when inotrope and vasopressor infusions were no longer 
needed. Time to removal varied substantially 4.2 (2.8) [1‐12] days. In the 
first patients of the cohort, the catheter stayed in for 5 days after op‐
eration. This gradually decreased to 1 day in the last two patients. One 
patient had PiCCO monitoring up to 12 days post‐transplantation due 
to an increased need for sedatives leading to hemodynamic instability, 
excessive fluid administration, pulmonary edema, prolonged ventila‐
tion, and delirium. After this, new protocols aimed at cessation of seda‐
tion and ventilation within 24 hours after transplantation, consequently 
reducing the duration of hemodynamic support and monitoring.
None of the kidneys showed delayed graft failure or early graft 
rejection. Patient and graft survivals were both 100% at 6 months 
after kidney transplantation.
4  | DISCUSSION
In this pilot study, TPTD appeared a feasible and safe technique to 
measure CO during LDKT with large donor‐recipient size mismatch. 
This is also the first report to quantify CO changes in these patients 
using a method that was recognized as gold standard for children.9,10 
After transplantation, cardiac index increased with 31% (95% 
CI = 15%‐48%). An unambiguous answer to the question whether 
CO‐guided hemodynamic therapy restricts intraoperative fluid ad‐
ministration was not found. Our results suggest that there was a 
trend toward less fluids given in favor of vasopressor use to achieve 
target ABP. Postoperative renal function was excellent.
4.1 | Feasibility and safety
The TPTD‐CO monitor has shown its feasibility, reliability and 
safety in pediatric intensive care for many years.14 Our results con‐
firm these findings and show that this method can be used during 
pediatric kidney transplantation when large hemodynamic changes 
are expected. Cardiac output measurements were easily performed 
and did not interfere with surgical activities. Concerns about the 
intra‐arterial catheter needed for this technique are thrombosis 
and ischemia of the limb distal to the catheter. These complications 
have been reported in neonates and infants with severe systemic 
circulation problems.15 In our patients, no such problems were en‐
countered despite a prolonged use in some of them. This might be 
explained by their relatively older age and the absence of sepsis or 
circulatory shock. Clearly, the benefits of a CO monitor using an in‐
dwelling arterial catheter should always be weighed against its risks.
4.2 | Physiology
Hemodynamic changes after reperfusion of the donor kidney reflect 
those occurring after suddenly opening a large arterio‐venous shunt 
as described by Guyton and Sagawa in 1961.16 In their model, open‐
ing this shunt resulted in a sudden reduction of the systemic vascular 
resistance, causing an increased CO and subsequent increase in ve‐
nous return. These hemodynamic changes occur also after creating 
an arterio‐venous‐fistula in adults.17 The resultant initial decrease in 
ABP is counteracted by the baroreceptor reflex, increasing HR and 
systemic vascular resistance. When this reflex is suppressed, as during 
anesthesia, hypotension is likely to occur. Thus, both CO and the sys‐
temic vascular resistance must increase to maintain an adequate ABP.
Our results are concordant with this mechanism. We found a 
31% increase in CI between t0 and t2, which is similar to reported 
values.3,4 Furthermore, our baseline CI values correspond well with 
those obtained in normal children. The difference with CI values ob‐
tained by Krovetz18 is 0.08 (95%CI = −0.52‐0.68) L min−1 m−2. At t2, 
all hemodynamic support had been stopped. Therefore, CO increase 
between t0 and t2 can be attributed to the relatively large donor kid‐
ney, despite the pharmacological effects of anesthetics and volume 
loading during transplantation and in the ICU. The absence of general 
anesthesia at t2 obviously aided the increase in HR. The increase in 
MAP between t0 and t2 suggests a permanent restoration of sys‐
temic vascular resistance, aided by the absence of anesthetics at t2.
4.3 | Hemodynamic therapy
4.3.1 | Pressure‐guided
Considering the described mechanism, hemodynamic therapy 
guided only by ABP and CVP lacks physiological grounds. Although 
an adequate ABP is necessary to prevent acute kidney injury, ABP 
values alone only provide limited information on renal perfusion and 
oxygenation.19 CVP is influenced by many factors and is known to 
be insufficient to predict fluid status.7,20 Studies in adults show that 
delayed graft function in kidney transplantation is related to postop‐
erative ABP but not to CVP.21 Moreover, higher CVP levels and fluid 
overload are associated with higher risks of acute kidney injury, renal 
replacement therapy, and mortality in critically ill children.22,23 In a 
retrospective analysis, postoperative renal replacement therapy was 
related to high volumes of intra‐operative fluid administration re‐
lated to body weight and a higher donor‐recipient weight ratio.5 This 
supports the idea that CVP‐guided fluid administration may lead to 
tissue edema, especially in small children.
4.3.2 | Flow‐guided
Optimal renal blood flow and pressure are of paramount importance 
to prevent hypoperfusion, delayed graft function, and subsequent 
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loss of renal tissue. Especially in small children, it is a challenge to 
achieve this as both hypovolemia and excess fluids are detrimental 
for the renal microcirculation. It would be ideal if renal flow, pres‐
sure, and microcirculation could be estimated. Our algorithm uses 
second bests as CO (renal flow), MAP (renal perfusion pressure) and 
fluid responsiveness (volume status). With the currently available 
hemodynamic monitors fluid responsiveness is difficult to assess in 
children.20 CO measurements also cannot directly estimate fluid re‐
sponsiveness, but are able to exhibit the effects of fluid loading and 
vasopressor therapy on CO.
4.3.3 | Norepinephrine
In addition to fluids, we administered dobutamine and norepineph‐
rine to support CO and ABP. Using dobutamine did not result in 
tachycardia. Norepinephrine was administered to support ABP by 
counteracting the depressant effects on systemic vascular resist‐
ance of (a) anesthetics and anti‐hypertensive drugs, (b) opening the 
arterial anastomosis and (c) cytokines released after reperfusion of 
the (ischemic) donor kidney. After an ischemic period, autoregula‐
tory mechanisms in the donor kidney might be disturbed and phar‐
macological support may be needed to guarantee an adequate 
perfusion pressure. In the past, concerns existed on the vasocon‐
strictive aspects of norepinephrine and its possible negative effects 
on visceral organ perfusion. Recent studies show otherwise: in a 
vasodilated state norepinephrine can even improve renal blood flow. 
It is currently the drug of choice to prevent hypotension in septic 
shock without increasing the incidence of acute kidney injury.24 In 
our patients, maximum doses were reached shortly after reperfu‐
sion and were only needed for a few hours and tapered down in the 
ICU after reduction in the level of sedation. Administration stopped 
before PiCCO‐catheter removal. Our results suggest that CO‐guided 
administration of norepinephrine can be used to achieve target ABP 
without negative effects on renal outcome.
4.3.4 | Fluids
As CVP and EVLWI did not increase despite fluid loading, we sug‐
gest that our hemodynamic strategy did not cause fluid overload. 
Prolonged time to tracheal extubation can be a sign of pulmonary 
edema and fluid overload. In our study, the moment of extubation 
depended on many variables, including potential signs of fluid over‐
load and the sedation protocol. The latter was optimized during the 
study, which gradually led to shorter time to extubation. Table 2 
shows that the last five patients could be extubated on the day of 
transplantation.
To assess whether our strategy led to less intraoperative fluids, 
there were only two recent studies to compare our results with, al‐
though the cohorts differ in age, weight, and the allograft source.5,6 
Compared with Michelet's study,5 we gave 25% less crystalloids to 
the last 10 patients and no albumin. Our fluid amounts were similar 
to those found in Taylors study,6 expressed as mL kg−1 h−1. However, 
this disregards the fact that all our patients weighed <20 kg vs 36.2 kg 
for Taylor's average patient. Our last 10 patients received 4.9 (1.2) 
[2.8‐6.3] times their basic fluid requirement calculated with the 4‐2‐1‐
rule vs 8.1 times for Taylor's average patient. Obviously, prudence is re‐
quired in judging the validity of this calculation for the average patient.
4.4 | Alternative CO‐monitoring
Although the TPTD‐CO monitor uses a validated and reliable tech‐
nique, it is invasive and requires experience. Echocardiography 
is less invasive and can supply the physician with useful informa‐
tion but has several limitations, such as technical problems during 
surgical procedures, operator dependency, and variability. Non‐ or 
minimally invasive CO monitors are easily applicable but also require 
experience while their reliability is questionable in young children 
and at best may be used as a trend monitor.25 Apparently, there is in‐
creasing interest in advanced hemodynamic monitoring in pediatric 
kidney transplantation. Especially, esophageal doppler monitoring26 
seems to gain popularity in this field. Although it is still difficult to 
show an unambiguous impact on outcome, monitoring the effect of 
fluids, and vasopressor support on CO makes sense as a cornerstone 
in hemodynamic management. Above all, the usefulness of any CO‐
monitor depends on the operators' experience and knowledge of the 
technical reliability issues.
4.5 | Limitations
Our study did not use a control group without CO monitoring. The 
first 12 patients in our program served as a pilot cohort to test the 
feasibility and safety of our hemodynamic monitoring and therapy 
plan. As we considered CO‐guided hemodynamic support as best 
clinical practice, we omitted a control group. Our cohort was small 
but consistent in age, weight, type of donor and short cold ischemia 
times. This consistency and the uniform hemodynamic protocol make 
our findings rather robust. Other studies show considerable varia‐
tion in recipients' age and weight, donor characteristics and hemo‐
dynamic therapy, which makes comparisons difficult. Nevertheless, 
the small number of patients should let us refrain from very broad 
conclusions on safety and risk‐benefit ratio.
In conclusion, a kidney transplantation with large donor‐re‐
cipient size mismatch implies clinically significant hemodynamic 
changes, illustrated by a 31% increased CO. The TPTD‐technique 
proved to be feasible and safe in this cohort. The results suggest 
that optimizing hemodynamics using a CO‐guided hemodynamic 
therapy algorithm to titrate inotropes, vasopressors, and fluids 
may reduce intra‐operative fluid administration compared with a 
CVP‐guided approach, thus possibly preventing tissue edema. As 
this is a small cohort, further research is desirable focusing on the 
most efficient algorithm and outcome effects of CO‐guided fluid 
therapy in these patients.
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